Selective RET-inhibitors such as selpercatinib and pralsetinib are effective therapeutic options for RET -altered tumors, and both compounds have shown considerable intracranial efficacy of 91% in RET fusion-positive NSCLC in the pivotal studies [39, 40]. Here, RET is linked to non-small cell lung carcinoma.